26th week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220202719 | FREEZE-DRIED PRODUCT AND GAS-FILLED MICROVESICLES SUSPENSION - A method of manufacturing a suspension of gas-filled microvesicles by reconstituting a freeze-dried product and a suspension obtained according to said method, where the freeze-dried product has been subjected to a thermal treatment | 2022-06-30 |
20220202720 | SUSTAINED RELEASE COMPOSITION COMPRISING TAPENTADOL OXALATE AND METHOD OF PREPARATION THEREOF - The present invention relates to a sustained release composition comprising Tapentadol or a pharmaceutically acceptable salt thereof for oral administration for the treatment of severe chronic pain in adults. | 2022-06-30 |
20220202721 | ARTICLES AND METHODS FOR ADMINISTRATION OF THERAPEUTIC AGENTS - Articles and methods for delivering a therapeutic agent to a subject are described. These articles and methods may be useful, in some cases, for the delivery of therapeutic agents to the colon of a subject. In some embodiments, an article is configured to release a secretion inducing agent e.g., to stimulate the release of intestinal fluids. The article, in some embodiments, comprises a therapeutic agent such that the stimulated release of intestinal fluid increases the amount of therapeutic agent available for absorption by the colon. For example, in some embodiments, the articles and methods described herein advantageously promote increased absorption of therapeutic agents in subjects as compared to traditionally administered therapeutic agents without additional components such as a secretion inducing agent. In some embodiments, articles and methods described herein may increase the motility of the colon of a subject. The increase in contractions and movement of fluidic in the colon caused by increase motility may advantageously facilitate the dissolution or absorption of the therapeutic agent. | 2022-06-30 |
20220202722 | ORODISPERSIBLE TABLET - The present invention is directed to a composition in the form of an orodispersible tablet comprising a non-steroidal anti-inflammatory drug (NSAID) and a taste-masking agent wherein the NSAID is uncoated and has an average particle size of less than 100 μm. The present invention is further directed to the use of malic acid as a taste-masking agent. | 2022-06-30 |
20220202723 | LEVODOPA DOSING REGIMEN - The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease. | 2022-06-30 |
20220202724 | BIOERODIBLE DRUG DELIVERY DEVICES - This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment. The bioerodible drug delivery device can be used to deliver a wide variety of different pharmaceutically active agents, and can do so at a controlled rate and over an extended period of time. The bioerodible drug delivery device includes a bioerodible polymeric outer housing with one or more delivery ports for delivering the pharmaceutically active agent(s) contained therein. The polymer used as the bioerodible polymeric outer housing is not substantially degraded during the dosing of the pharmaceutically active agent(s) in the bioerodible drug delivery device. The invention also provides methods of making the bioerodible drug delivery device and using it for the treatment of diseases and disorders. | 2022-06-30 |
20220202725 | Modified or Targeted Release Formulations of Linaclotide - The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions. | 2022-06-30 |
20220202726 | NEW DRY POWDER COMPOSITION FOR PERORAL ADMINISTRATION - There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and/or a volume-based mean diameter, and/or a structural/particle density, that is/are similar to the weight- and/or volume-based mean diameter, and/or the structural/particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and/or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage. | 2022-06-30 |
20220202727 | HYDROGEL COMPOSITIONS COMPRISING ENCAPSULATED CELLS AND METHODS OF USE THEREOF - The present invention provides injectable compositions comprising cells encapsulated in hydrogel capsules and methods of preparing these compostions. The present invention also provides methods for using these compositions to promote hematopoiesis and to treat or prevent cardiovascular and immunological disorders in a subject. | 2022-06-30 |
20220202728 | METHODS FOR PRODUCING A PHARMACEUTICAL CARRIER - A formulation for injection moulding of a pharmaceutical carrier comprising 27-85% (w/w) of polyvinyl alcohol, and 10-60% (w/w) of a disintegration aid selected from maize starch, wheat starch, and combinations thereof; and optionally one or more excipients. | 2022-06-30 |
20220202729 | NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION - According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage. | 2022-06-30 |
20220202730 | 5-AMINOLEVULINIC ACID FOR THE LOCAL TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to the therapeutic use of compositions containing 5-aminolevulinic acid for the local treatment of inflammatory bowel disease, including but not restricted to ulcerative colitis and Crohn's disease. | 2022-06-30 |
20220202731 | BIO-COMPATIBLE POLYURETHANE MICROCAPSULES AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to partially bio-based and bio-compatible polyurethane microcapsules. More particularly, the present invention relates to partially bio-based and bio-compatible polyurethane microcapsules for sustained release of an active ingredient. The present invention also relates to a process for the preparation of the partially bio-based and bio-compatible polyurethane microcapsules. | 2022-06-30 |
20220202732 | Metal Oxide Encapsulated Drug Compositions and Methods of Preparing the Same - A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials is provided. The method includes the sequential steps of (a) loading the particles comprising the drug into a reactor, (b) applying a vaporous or gaseous metal precursor to the particles in the reactor, (c) performing one or more pump-purge cycles of the reactor using inert gas, (d) applying a vaporous or gaseous oxidant to the particles in the reactor, and (e) performing one or more pump-purge cycles of the reactor using inert gas. The temperature of the particles does not exceed 35° C. This produces a pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials. | 2022-06-30 |
20220202733 | PROTEIN NANO- OR MICROPARTICLES AS ARTIFICIAL INCLUSION BODIES - The invention relates to protein particles comprising a cluster of one or more types of assembled self-contained protein, wherein the particle has a size from 50 nm to 50 micrometers; is in form of a pellet in aqueous media; is mechanically stable; and it release a particular percentage by weight of the self-contained protein within a predetermined period of time, and any other compound contained in the particle. Particular methods for obtaining the particles are also disclosed, said methods comprising the addition of salts to allow precipitation of proteins. Particular protein particles comprising lipids associated with the assembly of self-contained proteins are also disclosed. The invention also relates to several uses of the particle, in particular medical uses and to pharmaceutical and cosmetic compositions comprising the particles. | 2022-06-30 |
20220202734 | HYALURONIC ACID-BASED DISSOLVING FILM, PRODUCTION METHOD THEREOF, AND RELEASE LINER USED FOR THE SAME (as amended) - The present invention relates to a hyaluronic acid-based dissolving film, a production method thereof, and a release liner used for the same, and more particularly to a method for producing a hyaluronic acid-based dissolving film that provides a hyaluronic acid-based dissolving film having high performance with high productivity through a continuous production process to allow mass production of the dissolving film, a hyaluronic acid-based dissolving film produced by the method, and a release liner suitable for the dissolving film. | 2022-06-30 |
20220202735 | METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS - The subject invention relates to novel micoparticulate and soluble forms of flavonoids, and their synthesis. The invention also includes novel formulations of such flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations. | 2022-06-30 |
20220202736 | COVERING FILM, SYSTEM COMPRISING SAME, AND USAGE METHOD AND APPLICATION THEREFOR - A medical covering film and system, and a usage method and an application therefor. The medical covering film comprises a barrier film layer ( | 2022-06-30 |
20220202737 | TREATMENT OF HIDRADENITIS SUPPURATIVA WITH TAPINAROF COMPOSITIONS - The present invention, in some embodiments thereof, relates to treatment of hidradenitis suppurativa by topical or intralesional administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention or amelioration of hidradenitis suppurativa. | 2022-06-30 |
20220202738 | CANNABINOIDS IN THE TREATMENT OF EPILEPSY - The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). | 2022-06-30 |
20220202739 | ENDOCANNABINOID MIMETIC AND ANTI-INFLAMMATORY COMPOUND CONTAINING COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF - A composition comprising direct, indirect and related pathway endocannabinoid mimetic compounds and methods of using the composition. | 2022-06-30 |
20220202740 | ORAL COMPOSITIONS COMPRISING CINNAMALDEHYDE AND USES THEREOF - Oral compositions comprising cinnamaldehyde, and methods or improving circulation and improving circulation by administering such compositions, are described. Methods and uses are describe that include the administration of an effective amount of the oral compositions to improve circulation and increasing nerve sensitization, while also resulting in improved balance, and reduced pain, numbness, and/or tingling in the hands and feet, as well as reduced restlessness, fatigue, and tiredness of the legs. | 2022-06-30 |
20220202741 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 - The invention provides methods and compositions for treatment of a subject with a glioma that has failed treatment with temozolomide (TMZ) comprising administration of a composition comprising a Coenzyme Q10 compound to the subject. The invention also provides a method of treating a cancer that exhibits increased Complex II activity in a subject comprising administration of a composition comprising a Coenzyme Q10 compound to the subject. | 2022-06-30 |
20220202742 | DOSAGE FORMS FOR PREVENTING DRUG-FACILITATED ASSAULT - Disclosed herein are immediate release oral dosage forms that comprising esketamine and one or more excipients that produce a visual indication of the presence of the dosage form within a vessel containing a liquid beverage. The visual indication can assist in thwarting an attempt to use the esketamine to render another individual more susceptible to criminal exploitation. | 2022-06-30 |
20220202743 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE USING AUTOPHAGY ACTIVATION - The present invention relates to a pharmaceutical composition for preventing or treating a degenerative brain disease, and a pharmaceutical composition may be provided for preventing or treating a degenerative brain disease, which comprises one or more selected from the group consisting of a compound represented by the following Chemical Formula 1 and a pharmaceutically acceptable salt thereof as an active ingredient. | 2022-06-30 |
20220202744 | METHODS OF TREATING MENTAL DISORDERS - This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose. | 2022-06-30 |
20220202745 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT - The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE. | 2022-06-30 |
20220202746 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition is described. The composition comprises: (i) a drug component consisting of salmeterol xinafoate and fluticasone propionate. and (ii) a propellant component at least 90 wt % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition. | 2022-06-30 |
20220202747 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SHIGA TOXICOSIS - Methods for treating Shiga toxicosis, caused by infection with Shiga toxin bacteria, are provided. The methods include administering to a subject in need thereof an effective amount of one or more active agents selected from tamoxifen, 4-hydroxytamoxifen, endoxifen, toremifene, raloxifene, bazedoxifene, and pharmaceutically acceptable salts thereof. In some embodiments, the methods further include the administration of an antibiotic or a manganese compound to the subject. Pharmaceutical compositions for the treatment of Shiga toxicosis are also described. | 2022-06-30 |
20220202748 | SCALP COOLING HAIR PRODUCT - The present invention relates generally to new and improved compositions and methods for producing reliable relief from irritation or itching of the skin of the scalp. | 2022-06-30 |
20220202749 | METHODS FOR MAKING AND USING PHARMACEUTICAL COMPOSITIONS FOR IONTOPHORESIS - Methods of making and using pharmaceutical compositions for iontophoresis that include selecting an isotonic pharmaceutical composition that has ions of active and non-active ingredients and reducing/removing the ions of the non-active ingredients from the pharmaceutical composition to produce a revised pharmaceutical composition. The revised pharmaceutical composition is thereafter utilized for iontophoresis in an iontophoresis system. During the step of performing iontophoresis with the revised pharmaceutical composition for a pre-determined dosage, ramp-up period, maximum current, overall time, etc., can be reduced, as compared to performing iontophoresis with the isotonic pharmaceutical composition to provide the pre-determined dosage. | 2022-06-30 |
20220202750 | DYE COMPOSITION FOR MARKING ORGANIC TISSUE WITH ANAESTHETIC AND METHOD FOR APPLYING SAME - The present invention relates to the technical field of dyes for marking organic tissue. It relates to a dye whose composition contains pigments, topical anaesthetics and absorption potentiator, used to visually mark a specific area of the surface of the organic tissue and concomitantly anaesthetize the marked area. The anaesthetic dye can be applied with a pen/stick. The invention simplifies procedures that require the marking of an anaesthetized region for subsequent intervention, saving time and anaesthetic and providing greater safety for patients. A method for applying said composition is also provided. | 2022-06-30 |
20220202751 | MINI SOFTGEL NAPROXEN COMPOSITION - Disclosed herein are mini softgel capsules comprising a reaction product of naproxen free acid and potassium hydroxide in a molar ratio of potassium hydroxide to naproxen free acid of less than about 1. Also disclosed herein are methods for treating patients in need thereof with the mini softgel capsules as well as methods for stabilizing mini softgel capsules that include a fill composition that has a high concentration of active agent. | 2022-06-30 |
20220202752 | NOVEL PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition for treating or preventing acidosis in chronic kidney disease with anemia, the pharmaceutical composition containing citric acid, a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof, in which the pharmaceutical composition is in a form of a tablet. | 2022-06-30 |
20220202753 | METHOD OF DELIVERY OF INTRAVENOUS BACLOFEN - Methods for the intravenous (IV) administration of a therapeutically effective amount of baclofen at a dosing regimen which mimics the oral pharmacokinetic profile of baclofen are disclosed. The disclosed methods meet bioequivalence criteria for both systemic exposure (AUC) and maximum plasma concentration (C | 2022-06-30 |
20220202754 | USES OF PANTOTHENIC ACID IN PREPARATION OF A COMPOSITION FOR TREATING AND/OR PREVENTING TUMORS - Provided is a use of pantothenic acid in preparation of a composition for treating and/or preventing tumors. The present disclosure also discloses a use of metabolites of intestinal bacteria comprising pantothenic acid in preparation of a composition for treating and/or preventing tumors. Also provided is a use of intestinal bacteria capable of secreting metabolites comprising pantothenic acid in preparation of a composition for treating and/or preventing tumors. Pantothenic acid and metabolites of intestinal bacteria comprising pantothenic acid can significantly promote the accumulation of CD8 | 2022-06-30 |
20220202755 | FORMULATIONS OF L-ORNITHINE PHENYLACETATE - Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders. | 2022-06-30 |
20220202756 | GENETIC VARIANTS ASSOCIATED WITH RESPONSE TO TREATMENT OF NEUROLOGICAL DISORDERS - Method of treating depression, major depressive disorder, suicidal ideation and related disorders are described by administering L-4-chlorokynurenine (L-4-CI-KYN) to a subject based on their genotype. | 2022-06-30 |
20220202757 | PROTEIN SUBSTITUTE AMINO ACID COMPOSITIONS AND PRODUCTS, AND OTHER FOOD AND BEVERAGE PRODUCTS - Protein substitute products that furnish nutrients include amino acid compositions that include essential amino acids and non-essential amino acids in a preferred ratio, along with Vitamins, nutrients and botanicals provided as a food or beverage product that provides sustenance. Amino acids are provided in ratios and with other components to stimulate production of mitochondria in the cells and increase mitochondrial density in each cell type, including in particular muscle cells. Compositions may include simple and complex sugar producing carbohydrates to provide a short to medium energy source to the production of ATP by the mitochondria. | 2022-06-30 |
20220202758 | Methods and compositions for the treatment of diverticulosis - The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis. | 2022-06-30 |
20220202759 | Pet Food Compositions Comprising Caprylic Acid and Docosahexaenoic Acid and/or Eicosapetaenoic Acid for Use in Treating Struvite Urolithiasis - Disclosed herein are pet food compositions for treating or preventing—inter alia—struvite urolithiasis comprising at N least one of caprylic acid and capric acid; and at least one of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). | 2022-06-30 |
20220202760 | CNS MODULATORS - A method is provided for treating a subject in need of therapy for depression, anxiety, impaired cognition and/or pain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide anti-depressant effect, cognition enhancing and/or analgesic effect. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM. | 2022-06-30 |
20220202761 | DIAPER CREAM - Materials and methods for formulating skin care compositions suitable for use on babies and toddlers are provided herein. For example, this document provides materials and methods for formulating diaper cream compositions that contain natural ingredients, are not irritating to babies' skin, and can be used to treat or prevent symptoms of diaper rash. | 2022-06-30 |
20220202762 | BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES - A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay. | 2022-06-30 |
20220202763 | ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN - Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than | 2022-06-30 |
20220202764 | PHARMACEUTICAL, PHYTO-CANNABINOID BASED COMPOSITIONS - The present invention relates to a pharmaceutical composition comprising a combination of the cannabinoids tetrahydrocannabivarin (THCV), cannabigerol (CBG), cannabichromene (CBC) and tetrahydrocannabinol (THC) for use in the prevention or treatment of disorders related to depression, fatigue, deteriorated alertness, excessive daytime sleepiness and reduced appetite, wherein the relative weight ratios of THCV:CBG:CBC:THC are between 1-10:1-10:1-10:1-10, and to a method of treating a mammal in need thereof, said mammal suffering from a disorder related to depression, fatigue, deteriorated alertness, excessive daytime sleepiness and reduced appetite, wherein a combination of an effective amount of cannabinoids selected from the group consisting of tetrahdrocannabivarin (THCV), cannabigerol (CBG), cannabichromene (CBC) and tetrahydrocannabinol (THC), is administered to said mammal, wherein the relative weight ratios of THCV:CBG:CBC:THC are between 1-10:1-10:1-10:1-10. | 2022-06-30 |
20220202765 | CANNABINOID COMPOSITIONS AND METHODS OF USING - This disclosure describes compositions including cannabinoids and methods of using those compositions including, for example, to treat or prevent inflammation, as an immunosuppressant, and/or as an anti-cancer therapeutic. In some aspects, the cannabinoid is chosen from i) CBC, CBCA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBL, CBLA, CBN, CBNA, THCV, THCVA, and any combination thereof, and ii) an approximately 1:1 equimolar mixture of CBD:CBDA. | 2022-06-30 |
20220202766 | CENTRAL NERVOUS SYSTEM HEALTH SUPPLEMENT - An orally administered composition positively mitigates the progression of central nervous system diseases such as Alzheimer's, Parkinson's and Multiple Sclerosis. The composition consists of a lipid based blood brain barrier transport medium (Base Transport Sub-Formula) to which other elements (Functional Targeting Compound) may be integrated to mediate specific chemo-neurological dysfunction. It may be administered through the mouth as droplets a spray medium or a chewable tablet. | 2022-06-30 |
20220202767 | CANNABIS COMPOSITION - The invention relates to a method for treating cancer or a symptom associated with cancer. In particular, the present invention relates to a method for treating cancer or a symptom associated with cancer, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition comprising a | 2022-06-30 |
20220202768 | DIHYDROMYRICETIN NANOEMULSION FORMULATIONS AND METHODS FOR FORMING THEM - Nanoemulsion compositions, processes, and methods that include dihydromyricetin (DHM). | 2022-06-30 |
20220202769 | OZONIDES FOR TREATING OR PREVENTING VIRUS INFECTIONS - Described are methods of treating or preventing a virus in a subject comprising administering ozonides to the subject. | 2022-06-30 |
20220202770 | COMPOSITION FOR TREATING HEPATITIS B, AND METHOD FOR EVALUATING REPLICATION ACTIVITY OF HEPATITIS B VIRUS - An evaluation system for replication activity of HBV capable of visualizing and quantifying replication of HBV DNA in a short period of time inexpensively, safely, and rapidly and a method for evaluation using the system are developed and provided. Moreover, a novel composition for inhibiting HBV replication with a mode of action different from that of conventional anti-HBV drugs is developed and provided. A therapeutic agent for hepatitis B comprising as an active ingredient an HBV-Pol activity inhibitor consisting of a phosphorylation inhibitor that inhibits phosphorylation of a TxY motif present in Terminal protein region of HBV-Pol is provided. | 2022-06-30 |
20220202771 | Antidepressants for the Treatment or Prevention of Memory Loss and/or Cognitive Decline or Dysfunction in Aging - The present invention includes a method of treating or preventing memory loss in a subject suffering from a memory loss-related disease or aging, comprising, consisting essentially of, or consisting of, administering an effective amount of a serotonin-norepinephrine reuptake inhibitor (SNRI) to the subject, wherein the serotonin-norepinephrine reuptake inhibitor is duloxetine or active derivative thereof, such as a subject with memory complaints as part of the aging process, mild cognitive impairment, Alzheimer's disease or dementia and an elevated depressive endophenotype genotype (DepE). | 2022-06-30 |
20220202772 | COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS - The disclosure provides in one aspect a method of treating, ameliorating, and/or preventing toxicity caused by a ribosome inactivating protein (RIP) in a subject. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of at least one compound of the disclosure. | 2022-06-30 |
20220202773 | MATERIAL AND METHOD FOR TREATING CANCER - The invention relates in general to pharmaceutical compositions, means and methods for sustained release of therapeutic agents for local treatments. It relates in particular to means and methods for local treatment of cancer diseases by embedding lyophilized Mitomycin C in a slowly releasing biocompatible hydrogel applied to affected tissue. | 2022-06-30 |
20220202774 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SPINAL CORD INJURY OR SPINAL STENOSIS - Proposed is a pharmaceutical composition for prevention or treatment of spinal cord injury or spinal stenosis. The pharmaceutical composition contains 3-(4-chlorophenyl)-4-(4-aminosulfonyl-phenyl)-1-methyl-1H-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof. It was newly discovered that the compound inhibits activities of pro-inflammatory cytokines and PGE | 2022-06-30 |
20220202775 | DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS - The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I′) is also provided. | 2022-06-30 |
20220202776 | METHODS OF TREATING PAIN - The present application relates to a method of providing a therapeutic regimen for the treatment of pain, wherein said method comprises administering an oral liquid pharmaceutical composition comprising celecoxib or a pharmaceutically acceptable salt thereof to a subject in need thereof. | 2022-06-30 |
20220202777 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS - The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. | 2022-06-30 |
20220202778 | ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBROVASCULAR DISEASE - There are provided methods for treating or preventing a cerebrovascular disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an isotope-enriched compound or a pharmaceutical composition thereof, where the isotope-enriched compound has the general Formula (I) or is a pharmaceutically acceptable salt or ester thereof: | 2022-06-30 |
20220202779 | ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFOR - Disclosed is a solid dispersion and a preparation method therefor. The solid dispersion contains a glucokinase activator, an isotopic label thereof, or a medicinal salt thereof and a polymer support. Further disclosed is a solid dispersion composition containing the solid dispersion and an excipient. Also disclosed is an oral preparation of the glucokinase activator, containing the solid dispersion or the solid dispersion composition. Also disclosed is a tablet and a capsule of the glucokinase activator and a preparation method therefor. In addition, also disclosed is the uses of the solid dispersion, the solid dispersion composition and the oral preparations comprising the tablet and the capsule, which can be used for treating and/or preventing selected diseases or medical conditions and especially one or more diseases selected from type I diabetes mellitus, type II diabetes mellitus, impaired glucose tolerance, impaired fasting glucose and hyperglycemia. | 2022-06-30 |
20220202780 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF - The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor modulator or an inhibitor and a second therapeutically active agent, such as an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. | 2022-06-30 |
20220202781 | EXTERNAL PREPARATION - Provided is a dexmedetomidine-containing non-aqueous external preparation being capable of suppressing the precipitation of a crystal of dexmedetomidine in the preparation, and having satisfactory transdermal absorbability. The non-aqueous external preparation includes: (A) dexmedetomidine or a salt thereof; (B) an aliphatic alcohol having 10 to 12 carbon atoms; (C) a propylene glycol monoester of a fatty acid having 6 to 16 carbon atoms; (D) an organic acid; and (E) an organic acid salt. | 2022-06-30 |
20220202782 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF - The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide. | 2022-06-30 |
20220202783 | Use Of ADAM9 Inhibitor As Immunomodulator - The present disclosure relates to a use of an ADAM9 inhibitor in manufacture of an immunomodulator. The immunomodulator can change the distribution of immune cells in a tumor and increase the infiltration of the immune cells, thereby increasing the efficacy of cancer immunotherapy. Furthermore, the immunomodulator can be used to enhance an effectiveness of a cancer immunotherapy, and the ADAM9 inhibitor can be a compound of Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof. | 2022-06-30 |
20220202784 | METHODS AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF ANTIVIRAL AGENTS - Compositions and method of the present invention comprise novel formulations for increasing the effectiveness of antiviral agents and for preventing and treating symptoms associated with the common cold and viral infections. The present invention is directed to treating symptoms resulting from viral infections and diseases associated with Picomaviridae, Coronaviridae, Orthomyxoviridae, Paramyxovirinae, Reoviridae, and Adenoviridae. The novel formulations provided herein improve the therapeutic ratio of antiviral agents such as pleconaril. | 2022-06-30 |
20220202785 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS - The invention relates to a class of small molecule inhibitors of GPR68/OGR1, a proton-sensing/stretch-sensing/sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19. | 2022-06-30 |
20220202786 | METHODS FOR TREATMENT OF CANCER - A method for treating or preventing cancer in a subject comprising administering a treatment effective amount of a chemotype 4 compound. | 2022-06-30 |
20220202787 | ISOTHIAZOLIDINE 1,1-DIOXIDE AND 1,4-BUTAN SULTONE CONTAINING RAPAMYCIN DERIVATIVES AND USES THEREOF - Described herein are compounds of Formula (I) that are inhibitors of mTORC1, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions. | 2022-06-30 |
20220202788 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6- -DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CAR- BONITRILE - 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed. | 2022-06-30 |
20220202789 | ADMINISTRATION OF BERBERINE METABOLITES - In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds. | 2022-06-30 |
20220202790 | NOVEL SALTS OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS - Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer. | 2022-06-30 |
20220202791 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS - The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent. | 2022-06-30 |
20220202792 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES - The present disclosure provides methods and formulations for treating a patient suffering from one or more of chronic inflammatory injury, metaplasia, dysplasia or cancer of an epithelial tissue, which method comprises administering to the patient an agent that selectively kills or inhibits the proliferation or differentiation of pathogenic epithelial stem cells (PESCs) relative to normal epithelial stem cells in the tissue in which the PESCs are found. Representative epithelial tissues include pulmonary, genitourinary, gastrointestinal/esophageal, pancreatic and hepatic tissues. | 2022-06-30 |
20220202793 | SUSTAINED RELEASE LOCAL ANESTHETIC HYDROGEL COMPOSITION - A bioresorbable, sustained release pharmaceutical composition comprising: 1.8 wt % to 3.0 wt % methylcellulose and 0.1 wt % to 3.0 wt % hyaluronan in the form of a gel polymer matrix, and at least one local anesthetic agent, suitably ropivacaine, which may be administered by injection. | 2022-06-30 |
20220202794 | ANTITUMOR COMPOSITION - A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1): | 2022-06-30 |
20220202795 | PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HAVING DOUBLE-RELEASE PROFILE - The present disclosure relates to a pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, and particularly to a pharmaceutical composition which exhibits a dual release profile of immediate release and sustained release so that long-term efficacy can be sustained. The pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, according to the present disclosure, can secure bioavailability equivalent to that of existing esomeprazole immediate-release/enteric-release formulations, and can maintain long-term efficacy due to the dual release profile thereof even when administered once a day, thus preventing the occurrence of nocturnal acid breakthrough, and accordingly, can be effectively used as a therapeutic agent for nocturnal acid breakthrough. | 2022-06-30 |
20220202796 | CXCL10 Inhibitors - Provided herein are compounds and compositions effective for inhibiting CXCL10 gene expression, production, and secretion in mammalian cells, tissues and organs, as well as ameliorating its biological activity, along with a method for treatment of one or more disorders associated with an increase in CXCL10 gene expression, production, and secretion. | 2022-06-30 |
20220202797 | METHODS AND COMPOSITIONS FOR TREATING GASTRIC ULCERS - A method of treating and/or preventing gastric ulcers, said method comprising administering by injection a therapeutically effective amount of a composition comprising: c) a first agent selected from the group consisting of: a medium chain triglyceride and a long chain triglyceride; and d) a second agent comprising a proton pump inhibitor or pharmaceutically or veterinary acceptable salt, wherein the composition is adapted for sustained release of a therapeutically effective amount of the proton pump inhibitor to a subject in need thereof. | 2022-06-30 |
20220202798 | USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME - The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject. | 2022-06-30 |
20220202799 | PHARMACEUTICAL FORMULATIONS CONTAINING P2Y14 ANTAGONISTS - The invention provides formulations containing a P2Y14 antagonist, such as the naphthoic acid derivative PPTN, and an agent that increases the solubility of the P2Y 14 antagonist in an aqueous medium. The invention also provides methods of using the formulations to treat kidney disorders and conditions associated with renal inflammation. | 2022-06-30 |
20220202800 | Method of Treatment of Organic Acidemias and Other Mitochondria Defects or Deficiencies - Methods of treating a patient having an organic acidemia or a defect in mitochondria chain oxidation are provided. The methods comprise treating the patient with an effective amount of a mitochondria-targeting reactive oxygen species scavenger. | 2022-06-30 |
20220202801 | USE OF COMPOUND IN PREPARATION OF DRUG FOR TREATING ATHEROSCLEROSIS - Disclosed is use of a compound in the preparation of a medicament for treating atherosclerosis. The compound is selected from a group consisting of a compound of formula I, Nib2 and a pharmaceutically acceptable salt thereof. Based on the mechanism of atherogenesis, the invention started with the inhibition of inflammatory reaction. The research results showed that the compounds disclosed herein can significantly inhibit the macrophage foaming, reduce the deposition of lipidic necrotic substances, and reduce the formation of plaques, thus to some extent delaying or inhibiting atherosclerosis. | 2022-06-30 |
20220202802 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF KIDNEY DISEASES - The present invention discloses compounds according to Formula I: | 2022-06-30 |
20220202803 | COMBINATION THERAPIES INCLUDING INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE - The invention provides therapeutic methods that include providing to a subject an inhibitor of dihydroorotate dehydrogenase (DHODH) and a second therapeutic agent. The methods are useful for treating cancers, such as leukemias. | 2022-06-30 |
20220202804 | COMPOSITIONS AND METHODS TO TREAT CANCER - Provided herein are methods and combination therapies useful for the treatment of cancer. In particular, provided herein are methods and combination therapies for treating cancer by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and (b) at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof. | 2022-06-30 |
20220202805 | REBAMIPIDE FOR USE IN PREVENTION AND/OR TREATMENT OF SYNUCLEINOPATHIES - The present invention provides rebamipide for use in a method of prevention and/or treatment of a synucleinopathy, in particular of Parkinson's disease. In particular, rebamipide is used in prevention and/or treatment of a synucleinopathy in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability. | 2022-06-30 |
20220202806 | TREATMENT OF H-RAS-DRIVEN TUMORS - The present disclosure describes a compositions and methods for treatment of Hras-driven cancers. Administration of a farnesyltransferase inhibitor, for example, tipifarnib, alone or in combination with a MEK inhibitor can reduce tumor size and tumor growth in cancers such as poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) | 2022-06-30 |
20220202807 | Methods of Using Low Dose Naltrexone to Treat Chronic Pain - Methods of using low dose naltrexone to treat chronic pain in a patient. The methods of using low dose naltrexone to treat chronic pain generally includes administering to the patient a first amount of naltrexone in an immediate-release agent and a second amount of naltrexone in a modified-release agent. | 2022-06-30 |
20220202808 | Compositions For Affecting Weight Loss - Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity. | 2022-06-30 |
20220202809 | METHODS OF TREATING DEPRESSION WITH VORTIOXETINE - The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and/or different CYP2D6 metabolizer status. | 2022-06-30 |
20220202810 | METHODS OF TREATING PSYCHIATRIC DISORDERS IN OBESE PATIENTS WITH BREXPIPRAZOLE - The present disclosure relates to methods of initiating brexpiprazole treating in patients with schizophrenia or major depressive disorder. The present disclosure further relates to modified dosing regimens for obese patients and/or patients that are CYP2D6 poor metabolizers. In embodiments, the modified dosing regimens administers double the daily dose while initiating treatment. | 2022-06-30 |
20220202811 | TREATMENT FOR RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR Ɣ (RORƔ)-DEPENDENT CANCERS - Described are compositions and methods for the treatment of an RORγ-dependent cancer, including pancreatic cancer, lung cancer, leukemia, etc. In some example implementations, pharmaceutical compositions for cancer treatment comprising RORγ inhibitors and optionally other therapeutic agents, as well as methods of treating cancer using the pharmaceutical compositions are disclosed. | 2022-06-30 |
20220202812 | Use of ligustrazine nitrone derivatives in treatment and prevention of diabetic complication diseases - The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I). | 2022-06-30 |
20220202813 | AMORPHOUS SOLID DISPERSIONS - The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them. | 2022-06-30 |
20220202814 | TREATMENT OF CANCER - Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein are compositions and methods for the treatment of Ewing's Sarcoma. Said compositions comprise isoform selective pyrrolo-pyrazole PKC inhibitors. | 2022-06-30 |
20220202815 | TREATMENT OF CANCER - Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein are compositions and methods for the treatment of Ewing's Sarcoma. Said compositions comprise isoform selective pyrrolo-pyrazole PKC inhibitors. | 2022-06-30 |
20220202816 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS - The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions. | 2022-06-30 |
20220202817 | AMORPHOUS SOLID DISPERSION FORMULATION - The present disclosure provides an amorphous solid dispersion containing a Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration, wherein the Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof is dispersed in a matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing a above amorphous solid dispersion and a use thereof for treating virus infection and a pharmaceutical composition containing same. | 2022-06-30 |
20220202818 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER - A combination comprising a compound of Formula (I) and/or Formula (Ia), or a pharmaceutically acceptable salt thereof, and at least one immune checkpoint modulator. Methods for the prevention and treatment of a cancer comprises administering to a subject in need thereof, a therapeutically effective amount of a combination, the combination comprising: a compound of Formula (I) and/or Formula (Ia), or a pharmaceutically acceptable salt thereof, and at least one immune checkpoint modulator. | 2022-06-30 |